FDA Approves First Oral SERD Therapy for Resistant Breast Cancer
- SSCTR Exco
- Oct 1
- 1 min read
Published on LinkedIn (via Spencer Knight)
The FDA has approved Inliruqo™ (imlunestrant) from Eli Lilly, the first oral estrogen receptor degrader for ER+, HER2–, ESR1-mutated breast cancer. The therapy demonstrated significant improvements in progression-free survival and offers patients a more convenient oral option compared to injections like fulvestrant.
👉 Read the full article: Breakthrough in Breast Cancer: FDA approves Inliruqo™
Disclaimer
Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.
Comments